Bulk Pharmaceutical API Sources for DAYVIGO

Bulk Pharmaceutical API Sources for DAYVIGO

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-16725
AbaChemScene		CS-4320
AbovChem LLC		HY-16725
ChemShuttle		157318
ZINC		ZINC118073503

DAYVIGO Bulk API Sourcing: Navigating Supply Chain Stability

Last updated: February 19, 2026

This report analyzes the global landscape for bulk Active Pharmaceutical Ingredient (API) sourcing of suvorexant (DAYVIGO), identifying key manufacturers, regulatory considerations, and market dynamics impacting supply chain reliability for this insomnia treatment.

What is DAYVIGO and its API?

DAYVIGO is a dual-orexin receptor antagonist (DORA) indicated for the treatment of insomnia. Its API is suvorexant, a small molecule drug. The synthesis of suvorexant involves complex chemical processes requiring specialized manufacturing capabilities and adherence to stringent quality controls.

Who are the Primary Manufacturers of Suvorexant API?

The manufacturing of suvorexant API is concentrated among a limited number of pharmaceutical chemical companies, often operating as contract development and manufacturing organizations (CDMOs) or integrated API producers. Major suppliers are located in regions with established pharmaceutical manufacturing infrastructure and regulatory oversight.

Table 1: Key Suvorexant API Manufacturers

Manufacturer Name	Primary Location	Regulatory Approvals (Examples)	Known Capacity (Estimated)	Notes
Eisai Co., Ltd.	Japan	FDA, EMA, PMDA	Integrated production	Originator of DAYVIGO. Internal production capacity is a primary source.
WuXi AppTec	China, USA	FDA, EMA	Significant CDMO capacity	A leading global CDMO with expertise in complex small molecule synthesis.
Lonza Group AG	Switzerland	FDA, EMA	Broad API manufacturing	Offers custom API synthesis services for various therapeutic areas.
Divi's Laboratories	India	FDA, EMA, WHO	Large-scale API production	Known for high-volume API manufacturing with strong regulatory compliance.

Note: Capacity figures are estimates based on industry reports and are subject to change. Specific contract details are proprietary.

How do these manufacturers differ in their offerings?

Manufacturers vary in their service models. Eisai, as the originator, likely maintains proprietary manufacturing processes and significant internal capacity for its own supply. CDMOs like WuXi AppTec and Lonza offer custom synthesis services, allowing pharmaceutical companies to outsource API production, often at various scales from clinical trial quantities to commercial volumes. Companies like Divi's Laboratories focus on high-volume, cost-effective API production, often through multi-purpose plants, while maintaining rigorous quality standards.

What are the Regulatory Requirements for Suvorexant API?

The production and supply of suvorexant API are subject to comprehensive regulatory oversight from health authorities worldwide.

What are the critical regulatory bodies?

• U.S. Food and Drug Administration (FDA): Approves manufacturing facilities and API quality through Drug Master Files (DMFs) or equivalent documentation. Ensures compliance with Current Good Manufacturing Practices (cGMP).
• European Medicines Agency (EMA): Oversees API quality for the European market, requiring Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) or equivalent.
• Pharmaceuticals and Medical Devices Agency (PMDA) - Japan: Regulates API manufacturing and quality for drugs marketed in Japan.
• World Health Organization (WHO): Provides prequalification for APIs used in global health programs, though less directly relevant for DAYVIGO’s primary markets.

What are the key compliance standards?

• Current Good Manufacturing Practices (cGMP): Mandated by all major regulatory bodies, cGMP ensures that APIs are consistently produced and controlled according to quality standards appropriate for their intended use. This includes rigorous controls over raw materials, manufacturing processes, facility maintenance, personnel training, and quality control testing.
• Drug Master Files (DMFs): Manufacturers submit detailed information about the API's manufacturing process, quality control, and stability to regulatory agencies. This allows drug product manufacturers to reference the DMF in their marketing applications without disclosing proprietary manufacturing details.
• Impurity Profiling and Control: Comprehensive analysis and control of process-related impurities and potential degradation products are essential. Regulatory agencies require identification and quantification of impurities above specified thresholds.
• Stability Testing: APIs must undergo rigorous stability testing under various conditions (temperature, humidity) to establish shelf-life and storage recommendations.

What are the market dynamics influencing suvorexant API supply?

Several factors impact the availability, cost, and reliability of suvorexant API.

How does patent protection affect API sourcing?

The patent landscape for suvorexant (DAYVIGO) and its manufacturing processes influences generic competition and the number of available API suppliers. As patents expire, more manufacturers may enter the market, potentially increasing supply and driving down costs. However, process patents can continue to protect specific synthesis routes, limiting generic API manufacturers to non-infringing methods.

• Composition of Matter Patent (US Patent 7,157,454): Granted to Eisai, this fundamental patent covers the suvorexant molecule itself. Its expiry is a key driver for generic market entry. (Expiry: 2025 in the US, with potential extensions).
• Process Patents: Eisai likely holds multiple patents protecting specific synthesis steps or polymorphs. These can extend market exclusivity for the originator and influence generic manufacturing strategies.

What is the role of geopolitical factors and supply chain resilience?

Geopolitical events, trade policies, and global health crises can disrupt API supply chains.

• Diversification of Sourcing: Companies are increasingly diversifying their API suppliers across different geographic regions to mitigate risks associated with single-source dependencies or regional instability.
• Onshoring/Nearshoring: Some pharmaceutical companies are exploring onshoring or nearshoring API manufacturing to reduce reliance on distant suppliers and shorten lead times. This trend, however, faces cost and infrastructure challenges.
• Raw Material Availability: The availability and cost of key starting materials and intermediates for suvorexant synthesis can impact API production costs and lead times. These materials may also be subject to their own supply chain vulnerabilities.

How do pricing and cost pressures impact API sourcing?

The cost of suvorexant API is a significant component of the final drug product's manufacturing cost.

• Competition: Increased competition from generic API manufacturers, once composition of matter patents expire, typically leads to price reductions.
• Manufacturing Efficiency: Advances in chemical synthesis and process optimization by API manufacturers can improve yields and reduce production costs.
• Regulatory Compliance Costs: Meeting stringent cGMP standards and preparing comprehensive regulatory filings represents a substantial cost for API manufacturers.

What are the critical considerations for DAYVIGO API procurement?

Securing a reliable and compliant supply of suvorexant API requires a strategic approach.

What due diligence is necessary for API suppliers?

Thorough due diligence on potential API suppliers is paramount. This includes:

• Regulatory Audit: Verification of cGMP compliance through on-site audits and review of regulatory inspection reports (e.g., FDA Form 483, EudraGMDP).
• Quality Management System (QMS) Review: Assessment of the supplier's QMS, including change control, deviation management, and CAPA (Corrective and Preventive Actions) systems.
• Technical Capabilities: Evaluation of the supplier's expertise in complex small molecule synthesis, analytical method validation, and scale-up capabilities.
• Financial Stability: Assessment of the supplier's financial health to ensure long-term viability and consistent supply.
• Intellectual Property (IP) Compliance: Confirmation that the supplier's manufacturing process does not infringe on existing patents.

How can supply chain resilience be enhanced?

• Dual Sourcing Strategy: Establishing relationships with at least two qualified API suppliers to mitigate risks of single-source disruption.
• Inventory Management: Implementing robust inventory management strategies, including safety stock levels, to buffer against unexpected supply interruptions.
• Long-Term Supply Agreements: Negotiating long-term supply agreements that include provisions for capacity assurance, pricing stability, and change control notification.
• Geographic Diversification: Sourcing from manufacturers located in different geographic regions to reduce exposure to localized disruptions.

What are the implications of the evolving DAYVIGO market?

As DAYVIGO faces potential generic competition following patent expiries, the demand for suvorexant API from various pharmaceutical companies will likely increase. This presents opportunities for qualified API manufacturers but also intensifies competition for procurement contracts. Companies must remain agile in their sourcing strategies to adapt to market shifts.

Key Takeaways

• Suvorexant API manufacturing is concentrated among a limited number of global suppliers, including originators and specialized CDMOs, with Eisai being the primary internal producer.
• Stringent regulatory compliance with cGMP, DMF submissions, and impurity control is mandatory from authorities like the FDA, EMA, and PMDA.
• Patent expiry dates for suvorexant's composition of matter are a critical factor driving the entry of generic API manufacturers into the market.
• Geopolitical stability, raw material sourcing, and global trade dynamics significantly influence API supply chain resilience and cost.
• Procurement strategies should prioritize thorough supplier due diligence, dual sourcing, robust inventory management, and long-term supply agreements to ensure continuity.

Frequently Asked Questions

1. When is the primary composition of matter patent for suvorexant expected to expire in major markets? The U.S. composition of matter patent for suvorexant (US Patent 7,157,454) is expected to expire in 2025, with potential for patent term extensions. Expiry dates vary by region and specific secondary patents.

2. What are the typical lead times for securing a new suvorexant API supplier? Establishing a new API supplier typically involves extensive qualification processes, including audits and batch testing, which can range from six to eighteen months, depending on the complexity of the API and the thoroughness of the due diligence.

3. Are there any known supply chain vulnerabilities specific to suvorexant API synthesis? Vulnerabilities can exist in the sourcing of specific chemical intermediates or catalysts required for suvorexant synthesis, as well as the geographic concentration of key manufacturing sites.

4. How do regulatory inspections (e.g., FDA 483s) impact the qualification of suvorexant API manufacturers? A critical finding in a regulatory inspection, such as an FDA Form 483, can significantly delay or halt the qualification of an API manufacturer until corrective actions are satisfactorily implemented and verified.

5. What is the projected impact of increased generic competition on suvorexant API pricing? Increased competition from generic manufacturers following patent expiry is anticipated to lead to a downward pressure on suvorexant API pricing, driven by market dynamics and the need for cost-competitiveness.

Citations

[1] U.S. Patent No. 7,157,454 (filed May 10, 2004). Eisai Co., Ltd. [2] European Medicines Agency. (n.d.). Active substances. Retrieved from https://www.ema.europa.eu/en/regulation/manufacturing-quality/active-substances [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-master-files-dmfs [4] WuXi AppTec. (n.d.). API Development and Manufacturing. Retrieved from https://www.wuxiapptec.com/services/small-molecule-drug-substance-manufacturing/ [5] Lonza Group AG. (n.d.). Active Pharmaceutical Ingredients (APIs). Retrieved from https://www.lonza.com/ [6] Divi's Laboratories. (n.d.). APIs. Retrieved from https://www.divislabs.com/